Hereditary hemorrhagic telangiectasia presenting with severe nasal bleeding: an ENT perspective
DOI:
https://doi.org/10.18203/issn.2454-5929.ijohns20263399Keywords:
Hereditary hemorrhagic telangiectasia, Epistaxis, Telangiectasia, ENT manifestationsAbstract
Hereditary hemorrhagic telangiectasia (HHT), also known as Osler–Weber–Rendu syndrome, is a rare autosomal dominant vascular disorder characterized by mucocutaneous telangiectasia and visceral arteriovenous malformations. Recurrent epistaxis is the most common and often the earliest manifestation, frequently bringing patients to the otorhinolaryngologist. We report a case of a patient presenting with recurrent, spontaneous, and progressively severe nasal bleeding. Anterior rhinoscopy and diagnostic nasal endoscopy revealed multiple, discrete, bilateral telangiectatic lesions over the nasal septum, floor of the nasal cavity, and inferior turbinates, which bled on touch, making cauterization difficult at certain sites. Mucocutaneous telangiectasia over the lips and oral cavity with a positive family history supported the diagnosis. Based on clinical findings and established diagnostic criteria, a diagnosis of definite Hereditary Hemorrhagic Telangiectasia was made. The patient was managed with local nasal measures and supportive therapy. This case highlights the importance of early recognition of HHT by ENT specialists to enable timely diagnosis, appropriate management, and prevention of systemic complications.
References
Faughnan ME, Palda VA, Garcia-Tsao G, Geisthoff UW, McDonald J, Proctor DD, et al. International guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia. J Med Genet. 2011;48(2):73-87.
Shovlin CL. Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev. 2010;24(6):203-19.
Govani FS, Shovlin CL. Hereditary haemorrhagic telangiectasia: a clinical and scientific review. Eur J Hum Genet. 2009;17(7):860-71.
Guttmacher AE, Marchuk DA, White RI Jr. Hereditary hemorrhagic telangiectasia. N Engl J Med. 1995;333(14):918-24.
Dupuis-Girod S, Bailly S, Plauchu H. Hereditary hemorrhagic telangiectasia: from molecular biology to patient care. J Thromb Haemost. 2010;8(7):1447-56.
Yaniv E, Preis M, Hadar T. Endoscopic treatment of epistaxis in hereditary hemorrhagic telangiectasia. Am J Rhinol. 2006;20(3):321-4.
Whitehead KJ, Sautter NB, McWilliams JP. Effect of bevacizumab on epistaxis duration in hereditary hemorrhagic telangiectasia. JAMA. 2016;316(9):934-42.
Folz BJ, Tennie J, Lippert BM, Werner JA. Natural history and clinical management of epistaxis in patients with hereditary hemorrhagic telangiectasia. Am J Otolaryngol. 2005;26(2):114-8.
Geisthoff UW, Seyfert UT, Kübler M, Bieg B, Plinkert PK, König J. Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid. Thromb Res. 2014;134(3):565-71.
Watkinson JC, Clarke RW, editors. Scott-Brown’s Otorhinolaryngology, Head and Neck Surgery. 8th ed. CRC Press; 2018.
Flint PW, Haughey BH, Lund VJ, editors. Cummings Otolaryngology – Head and Neck Surgery. 7th ed. Elsevier; 2021.
Curaçao criteria for the diagnosis of hereditary hemorrhagic telangiectasia. Am J Med Genet. 2000;91(1):66-7.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Ankur Gupta, Khyati Kushwaha, Mithun, Awanish Verma

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.